You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmobarbital
Accession NumberDB01351
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
Structure
Thumb
Synonyms
5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-(3-methylbutyl)barbituric acid
5-Ethyl-5-isoamylbarbituric acid
5-Ethyl-5-isopentylbarbituric acid
Amobarbital
Amylobarbitone
Amytal
Barbamil
Barbamyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amytal Sodium 500mgpowder for solution500 mgintramuscular; intravenousEli Lilly Canada Inc1939-12-312003-07-30Canada
Amytal Sodium Cap 60mgcapsule60 mgoralPharmascience Inc1951-12-312004-03-05Canada
Amytal Sodium Pulvule 222 0.2gmcapsule200 mgoralPharmascience Inc1939-12-312004-03-05Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amytal Sodiuminjection, powder, lyophilized, for solution.5 g/5mLintramuscular; intravenousValeant Pharmaceuticals North America LLC2008-09-25Not applicableUs
Amytal Sodiuminjection, powder, lyophilized, for solution.5 g/5mLintramuscular; intravenousMarathon Pharmaceuticals, LLC2008-09-25Not applicableUs
International Brands
NameCompany
IsomytalNot Available
Brand mixtures
NameLabellerIngredients
Tuinal Pulvule 303Pharmascience Inc
Tuinal Pulvule 304Pharmascience Inc
Salts
Name/CASStructureProperties
Amobarbital sodium
ThumbNot applicableDBSALT001490
Categories
UNIIGWH6IJ239E
CAS number57-43-2
WeightAverage: 226.2722
Monoisotopic: 226.131742452
Chemical FormulaC11H18N2O3
InChI KeyInChIKey=VIROVYVQCGLCII-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
SMILES
CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionAmobarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Amobarbital also appears to bind neuronal nicotinic acetylcholine receptors.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9254
Blood Brain Barrier+0.949
Caco-2 permeable-0.5913
P-glycoprotein substrateSubstrate0.6471
P-glycoprotein inhibitor INon-inhibitor0.5906
P-glycoprotein inhibitor IINon-inhibitor0.9426
Renal organic cation transporterNon-inhibitor0.9307
CYP450 2C9 substrateNon-substrate0.7591
CYP450 2D6 substrateNon-substrate0.9011
CYP450 3A4 substrateNon-substrate0.663
CYP450 1A2 substrateNon-inhibitor0.879
CYP450 2C9 inhibitorNon-inhibitor0.7603
CYP450 2D6 inhibitorNon-inhibitor0.9299
CYP450 2C19 inhibitorNon-inhibitor0.7269
CYP450 3A4 inhibitorNon-inhibitor0.9422
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9105
Ames testNon AMES toxic0.691
CarcinogenicityNon-carcinogens0.8925
BiodegradationNot ready biodegradable0.944
Rat acute toxicity2.9884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.8963
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintramuscular; intravenous.5 g/5mL
Powder for solutionintramuscular; intravenous500 mg
Capsuleoral60 mg
Capsuleoral200 mg
Capsuleoral
Prices
Unit descriptionCostUnit
Amytal sodium 0.5 gram vial117.35USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157 °CPhysProp
water solubility603 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.07HANSCH,C ET AL. (1995)
logS-2.57ADME Research, USCD
pKa7.84SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.897 mg/mLALOGPS
logP1.87ALOGPS
logP1.89ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58 m3·mol-1ChemAxon
Polarizability23.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.4 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-4900000000-8b443325c415e154ac85View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kim HS, Wan X, Mathers DA, Puil E: Selective GABA-receptor actions of amobarbital on thalamic neurons. Br J Pharmacol. 2004 Oct;143(4):485-94. Epub 2004 Sep 20. [PubMed:15381635 ]
  2. Maynert EW: The alcoholic metabolites of pentobarbital and amobarbital in man. J Pharmacol Exp Ther. 1965 Oct;150(1):118-21. [PubMed:5855308 ]
  3. Tang BK, Kalow W, Grey AA: Amobarbital metabolism in man: N-glucoside formation. Res Commun Chem Pathol Pharmacol. 1978 Jul;21(1):45-53. [PubMed:684279 ]
  4. Soine PJ, Soine WH: High-performance liquid chromatographic determination of the diastereomers of 1-(beta-D-glucopyranosyl)amobarbital in urine. J Chromatogr. 1987 Nov 27;422:309-14. [PubMed:3437019 ]
  5. McCall WV: The addition of intravenous caffeine during an amobarbital interview. J Psychiatry Neurosci. 1992 Nov;17(5):195-7. [PubMed:1489761 ]
External Links
ATC CodesN05CA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with 7-Nitroindazole.
AcebutololAmobarbital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Amobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Amobarbital.
AcetazolamideAmobarbital may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Amobarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Agomelatine.
AldesleukinAmobarbital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amobarbital.
AliskirenAmobarbital may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amobarbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Amobarbital.
AmilorideAmobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Amobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Amobarbital.
AmisulprideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amitriptyline.
AmlodipineAmobarbital may increase the hypotensive activities of Amlodipine.
AmoxapineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Amobarbital.
Amyl NitriteAmobarbital may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineAmobarbital may increase the hypotensive activities of Apraclonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Amobarbital.
ArticaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Asenapine.
AtenololAmobarbital may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Azaperone.
AzelastineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amobarbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Amobarbital.
Azilsartan medoxomilAmobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Amobarbital.
BaclofenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Amobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Amobarbital.
BenazeprilAmobarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazideAmobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Amobarbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amobarbital.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Amobarbital.
BetaxololAmobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.
BisoprololAmobarbital may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Amobarbital.
BretyliumAmobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
BrimonidineAmobarbital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Amobarbital.
BumetanideAmobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amobarbital.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amobarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amobarbital.
CanagliflozinAmobarbital may increase the hypotensive activities of Canagliflozin.
CandesartanAmobarbital may increase the hypotensive activities of Candesartan.
CaptoprilAmobarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amobarbital.
CarbinoxamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carisoprodol.
CarteololAmobarbital may increase the hypotensive activities of Carteolol.
CarvedilolAmobarbital may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Amobarbital.
CetirizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Amobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amobarbital.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amobarbital.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amobarbital.
ChlorothiazideAmobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amobarbital.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amobarbital.
ChlorthalidoneAmobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorzoxazone.
CilazaprilAmobarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Amobarbital.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amobarbital.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Amobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clemastine.
ClevidipineAmobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonazepam.
ClonidineAmobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amobarbital.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amobarbital.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amobarbital.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amobarbital.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amobarbital.
CyclizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amobarbital.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Amobarbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.
DapagliflozinAmobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Amobarbital.
deramciclaneThe risk or severity of adverse effects can be increased when Amobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital.
DesipramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine.
DexmedetomidineAmobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amobarbital.
DextromoramideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amobarbital.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amobarbital.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amobarbital.
DiclofenamideAmobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Amobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydromorphine.
DiltiazemAmobarbital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dimenhydrinate.
DinutuximabAmobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amobarbital.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amobarbital.
DipyridamoleAmobarbital may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Amobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Amobarbital.
DoxazosinAmobarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Amobarbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Amobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Amobarbital.
DrotebanolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Amobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Amobarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Amobarbital.
EmpagliflozinAmobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilAmobarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Amobarbital.
EplerenoneAmobarbital may increase the hypotensive activities of Eplerenone.
EprosartanAmobarbital may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Amobarbital.
EsmololAmobarbital may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amobarbital.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amobarbital.
Etacrynic acidAmobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Amobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Amobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ezogabine.
FelbamateThe serum concentration of Amobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Felbamate.
FelodipineAmobarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Amobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amobarbital.
FexofenadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Amobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amobarbital.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amobarbital.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amobarbital.
FluspirileneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluvoxamine.
FosinoprilAmobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fospropofol.
FurosemideAmobarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Amobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amobarbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Amobarbital is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Amobarbital.
GuanfacineAmobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amobarbital.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amobarbital.
HeroinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Hexobarbital.
HydralazineAmobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideAmobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amobarbital.
HydroflumethiazideAmobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.
IndapamideAmobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Amobarbital.
IrbesartanAmobarbital may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amobarbital.
Isosorbide DinitrateAmobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateAmobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineAmobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipineAmobarbital may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amobarbital.
KetazolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketobemidone.
LabetalolAmobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Amobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Amobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amobarbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Amobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levetiracetam.
LevobunololAmobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amobarbital.
LevocabastineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amobarbital.
LevomilnacipranThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amobarbital.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amobarbital.
LisinoprilAmobarbital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amobarbital.
LosartanAmobarbital may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amobarbital.
Lu AA21004The risk or severity of adverse effects can be increased when Amobarbital is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Amobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Amobarbital.
MannitolAmobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Maprotiline.
MecamylamineAmobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amobarbital.
MelperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amobarbital.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amobarbital.
MetaxaloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methaqualone.
MethazolamideAmobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amobarbital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amobarbital.
MethsuximideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methsuximide.
MethyclothiazideAmobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaAmobarbital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.
MetipranololAmobarbital may increase the hypotensive activities of Metipranolol.
MetolazoneAmobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololAmobarbital may increase the hypotensive activities of Metoprolol.
MetyrosineAmobarbital may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Amobarbital.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.
MilnacipranThe risk or severity of adverse effects can be increased when Amobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
MinoxidilAmobarbital may increase the hypotensive activities of Minoxidil.
MirtazapineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amobarbital.
MoexiprilAmobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nabilone.
NadololAmobarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amobarbital.
NebivololAmobarbital may increase the hypotensive activities of Nebivolol.
NesiritideAmobarbital may increase the hypotensive activities of Nesiritide.
NicardipineAmobarbital may increase the hypotensive activities of Nicardipine.
NifedipineAmobarbital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Amobarbital.
NiludipineThe metabolism of Niludipine can be increased when combined with Amobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Amobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Amobarbital.
NimodipineAmobarbital may increase the hypotensive activities of Nimodipine.
NisoldipineAmobarbital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Amobarbital.
NitroglycerinAmobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussideAmobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olanzapine.
OlmesartanAmobarbital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amobarbital.
OpiumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Opium.
OrphenadrineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amobarbital.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Amobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amobarbital.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amobarbital.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amobarbital.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amobarbital.
PapaverineAmobarbital may increase the hypotensive activities of Papaverine.
ParaldehydeAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Amobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.
PenbutololAmobarbital may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Amobarbital.
PerindoprilAmobarbital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amobarbital.
PethidineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Amobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Amobarbital.
PhenytoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amobarbital.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Amobarbital.
PindololAmobarbital may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pizotifen.
PolythiazideAmobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Amobarbital.
PramipexoleAmobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam.
PrazosinAmobarbital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Amobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Amobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amobarbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Amobarbital.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amobarbital.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.
PromethazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Amobarbital.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amobarbital.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amobarbital.
PropoxycaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Propoxycaine.
PropranololAmobarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Amobarbital is combined with PSD502.
PyridoxineThe metabolism of Amobarbital can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Quazepam.
QuetiapineAmobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.
QuinaprilAmobarbital may increase the hypotensive activities of Quinapril.
QuinethazoneAmobarbital may increase the orthostatic hypotensive activities of Quinethazone.
RamelteonThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ramelteon.
RamiprilAmobarbital may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amobarbital.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amobarbital.
ReserpineAmobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amobarbital.
RiociguatAmobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Amobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.
RomifidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Romifidine.
RopiniroleAmobarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital.
RotigotineAmobarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Amobarbital is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amobarbital.
Sodium oxybateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Amobarbital.
SotalolAmobarbital may increase the hypotensive activities of Sotalol.
SpironolactoneAmobarbital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Amobarbital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tasimelteon.
TelmisartanAmobarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amobarbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Amobarbital.
TerazosinAmobarbital may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrodotoxin.
ThalidomideAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Amobarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amobarbital.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amobarbital.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amobarbital.
ThiothixeneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Amobarbital.
TiletamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiletamine.
TimololAmobarbital may increase the hypotensive activities of Timolol.
TizanidineAmobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amobarbital.
TolcaponeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Amobarbital.
TopiramateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Topiramate.
TorasemideAmobarbital may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amobarbital.
TrandolaprilAmobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Amobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amobarbital.
TrazodoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trazodone.
TriamtereneAmobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amobarbital.
TrichlormethiazideAmobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amobarbital.
TrimipramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Amobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amobarbital.
ValsartanAmobarbital may increase the hypotensive activities of Valsartan.
VerapamilAmobarbital may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Amobarbital.
VortioxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Amobarbital.
XylazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Amobarbital.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amobarbital.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Amobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Amobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital.
ZolazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amobarbital.
ZonisamideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amobarbital.
ZotepineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  4. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:48 / Updated on August 17, 2016 12:23